US Patent

US10189850 — CDK inhibitors

Formulation · Assigned to G1 Therapeutics Inc · Expires 2031-10-25 · 5y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds of formulae I, II, or III, and their pharmaceutically acceptable salts, as CDK inhibitors.

USPTO Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: US10189850
Jurisdiction: US
Classification: Formulation
Expires: 2031-10-25
Drug substance claim: No
Drug product claim: Yes
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.